The Israeli company’s solutions for enhancing bladder cancer and incontinence medications are expected to be ready next year The gel formula could be fast-tracked for approval as an orphan drug for a particularly difficult-to-treat urinary tract cancerA unique material that gels with body he

read more>>

BOTHELL, Wash. and VANCOUVER, British Columbia - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Spruce clinical trial, an investigator-sponsored, randomized, double-blind, placebo-controlled Phase 2 study evaluating OGX-427 in patients with previously

read more>>

Jerusalem - BioLineRx a biopharmaceutical development company, announced today that it has received all necessary regulatory approvals in the US to commence a Phase IIa trial for BL-8040, for the treatment of Acute Myeloid Leukemia (AMLThe study is a multicenter, open-label study under an IND, des

read more>>

Fort Lauderdale, Fla. - First-of-its-kind research presented today showed microwave ablation (MWA) therapy cut pain in half for patients with painful bone and soft-tissue tumors and took less time to complete than radiofrequency ablation. Pain relief lasted over 4 months on average and up to 15 Ap

read more>>

CAMBRIDGE, MA and PERTH, AUSTRALIA - Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and the University of Western Australia (UWA) today announced that they have entered into an exclusive, worldwide licensing agreement for intellectual property rights to support the development of exon-skipping drug "Th

read more>>

CAMBRIDGE, Mass. - Merrimack Pharmaceuticals, Inc., announced preclinical study results showing that the novel bispecific therapy MM-111 restored tumor sensitivity to the chemotherapy agent, paclitaxel, and HER2-targeted treatment, trastuzumab, in a HER2+ gastric cancer model. The research was Ove

read more>>

An experimental drug that spurs the immune system to fight cancer appeared to be safe and demonstrated anti-tumor activity against a variety of cancers in a small early stage study, researchers said on TuesdayThe drug, called MPDL320A, was discovered and is being developed by Roche's Genentech uni

read more>>

SUNNYVALE, Calif. - Pharmacyclics, Inc., announced that the Phase III clinical trial (RESONATE™-2), a monotherapy trial using ibrutinib versus chlorambucil in elderly patients with newly diagnosed chronic lymphocytic leukemia / small lymphocyctic lymphoma (CLL/SLL) has enrolled its fifth patient.

read more>>

Washington (USA) - PharmaMar, a biopharmaceutical company owned by Grupo Zeltia (ZEL.MC), presented five new trials with marine-based antitumour drugs Aplidin® and PM01183 at the 104th Annual Meeting of the American Association for Cancer Research (AACR), held in Washington, D.C. from 6 to 10 Apri

read more>>

Washington, USA - Glioblastoma multiforme (GBM) is the most severe form of brain cancer and progresses rapidly. With the first-line treatment (surgery, chemo-, and radiotherapy) the prognosis is poor with a median survival rate of 14 to 15 months. This makes novel treatment strategies highly Activ

read more>>